Transcription Factor Modulator

Abstract

The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to A transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof; or (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof.

1 . A transcription factor modulator comprising:
 (i) a pharmaceutically-effective amount of an HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof, or   (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or   (iii) combinations thereof.   
     
     
         2 . The transcription factor modulator of  claim 1 , wherein said modulator is a ubiquitin ligase comprising:
 (i) a pharmaceutically-effective amount of an HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof; or   (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or   (iii) combinations thereof.   
     
     
         3 . The transcription factor modulator of  claim 1 , wherein the HLS-5 polypeptide comprises the sequence set out in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, or a polypeptide substantially homologous thereto, or a functional fragment thereof. 
     
     
         4 . The transcription factor modulator of  claim 1 , wherein the HLS-5 polypeptide is expressed in vivo from a vector comprising a polynucleotide encoding HLS-5. 
     
     
         5 . The transcription factor modulator of  claim 4 , wherein the HLS-5 polynucleotide is selected from the group consisting of:
 (a) polynucleotides comprising the nucleotide sequence set out in SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5, or a functional fragment thereof;   (b) polynucleotides comprising a nucleotide sequence capable of hybridizing selectively to the nucleotide sequence set out in SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5, or a functional fragment thereof;   (c) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a) or (b);   (d) polynucleotides complementary to the polynucleotides of (a) or (b).   
     
     
         6 . The transcription factor modulator of  claim 5 , wherein the HLS-5 polynucleotide is operably linked to regulatory sequences capable of directing expression of said polynucleotide in a host cell. 
     
     
         7 . A method of modulating transcription factor activity in vivo comprising the step of administering to a subject in need thereof the transcription factor modulator of  claim 1 . 
     
     
         8 . The method of  claim 7 , wherein the transcription factor modulator will directly or indirectly prevent transcription factor function or activity. 
     
     
         9 . The method of  claim 7 , wherein the transcription factor modulator will directly or indirectly bring about or enhance transcription factor activity. 
     
     
         10 . A method of modulating transcription factor activity in vitro comprising the step of administering to cells:
 (i) a pharmaceutically-effective amount of an HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof; or   (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or   (iii) combinations thereof.   
     
     
         11 . A method for treating or preventing a condition associated with transcription factor dysregulation comprising the step of administering to a subject in need thereof:
 (i) a pharmaceutically-effective amount of an HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof; or   (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or   (iii) combinations thereof.   
     
     
         12 . The method of  claim 11 , wherein the condition will be directly affected by or controlled by transcription factors. 
     
     
         13 . The method of  claim 11 , wherein the administration of the transcription factor modulator improves, alleviates, or treats the condition by controlling the transcription factors associated with or affected by the condition.